SCHEMBL220071

SCHEMBL220071

O=C(Nc1cc(I)cc(I)c1)N(S)C(=O)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.37
RAB9A P51151 2/20 0.37
ALDH1A1 P00352 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KCNK3 O14649 1/20 0.37
KCNK9 Q9NPC2 1/20 0.37
ACP1 P24666 1/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
TDP1 Q9NUW8 3/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
CES1 P23141 1/20 0.35
MAPK1 P28482 1/20 0.35
PKM P14618 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MDM4 O15151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL220188 0.90 MEN1 (0.37) SMN1; SMN2RAB9AALDH1A1NPSR1KCNK3
SCHEMBL14859165 0.84 ALDH1A1 (0.51) SMN1; SMN2RAB9AALDH1A1NPSR1KCNK3
SCHEMBL5713541 0.82 THRB (0.51) SMN1; SMN2RAB9AKCNK3KCNK9MEN1
SCHEMBL220680 0.82 MEN1 (0.41) SMN1; SMN2RAB9AALDH1A1NPSR1KCNK3
SCHEMBL10608197 0.81 RAB9A (0.36) SMN1; SMN2RAB9ANPSR1MEN1KMT2A
SCHEMBL222250 0.79 MEN1 (0.36) SMN1; SMN2RAB9AALDH1A1NPSR1KCNK3
SCHEMBL5713553 0.78 NPC1 (0.62) SMN1; SMN2RAB9AALDH1A1KCNK9MEN1
SCHEMBL5713503 0.78 RAB9A (0.54) SMN1; SMN2RAB9AALDH1A1MEN1KMT2A
SCHEMBL14860314 0.74 NPC1 (0.50) SMN1; SMN2RAB9AALDH1A1NPSR1MEN1
SCHEMBL17311419 0.73 MTOR (0.43) SMN1; SMN2RAB9AALDH1A1KCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481544-B2 Antibacterial compositions BIOTA EUROPE LIMITED (GB) 2013-07-09 US disclosed
US-8389516-B2 Antibacterial compositions BIOTA EUROPE LIMITED (GB) 2013-03-05 US disclosed
EP-2034997-B1 ANTIBACTERIAL COMPOSITIONS BIOTA EUROPE LTD (GB) 2012-10-17 EP disclosed
US-20120004221-A1 Antibacterial Compositions BIOTA EUROPE LIMITED (GB) 2012-01-05 US disclosed
US-20110263590-A1 Antibacterial Compositions BIOTA EUROPE LIMITED (GB) 2011-10-27 US disclosed
US-7977340-B2 Antibacterial compositions PROLYSIS LTD. (GB) 2011-07-12 US disclosed
US-20090197877-A1 Antibacterial Compositions PROLYSIS LTD. (GB) 2009-08-06 US disclosed
EP-2034997-A1 ANTIBACTERIAL COMPOSITIONS Prolysis Limited (GB) 2009-03-18 EP disclosed
WO-2007148093-A1 ANTIBACTERIAL COMPOSITIONS PROLYSIS LTD. (GB) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004221-A1 Antibacterial Compositions CYCS, COX6C, RPS6 SMN1; SMN2 3141/4885RAB9A 3590/4885ALDH1A1 2843/4885
US-20090197877-A1 Antibacterial Compositions CYCS, COX6C, INTS6 SMN1; SMN2 3693/4885RAB9A 3588/4885ALDH1A1 3469/4885
US-20110263590-A1 Antibacterial Compositions CYCS, COX6C, RPS6 SMN1; SMN2 3013/4885RAB9A 3558/4885ALDH1A1 2924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.